These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39137632)

  • 21. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic prediction and immune checkpoint profiling in glioma patients through neddylation-associated features.
    Qi J; Li L; Gao B; Dai K; Shen K; Wu X; Li H; Yu Z; Wang Z; Wang Z
    Gene; 2024 Dec; 930():148835. PubMed ID: 39127414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients.
    An W; Ren C; Yuan L; Qiu Z; Wang P; Cheng Y; He Z; Han X; Li S; An Y
    Front Immunol; 2024; 15():1411072. PubMed ID: 39211050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response.
    Ye S; Yang B; Yang L; Wei W; Fu M; Yan Y; Wang B; Li X; Liang C; Zhao W
    Sci Rep; 2024 Jun; 14(1):14758. PubMed ID: 38926605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
    Zhang C; Li J; Wang H; Song SW
    Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
    Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
    Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Machine learning-based identification of a cell death-related signature associated with prognosis and immune infiltration in glioma.
    Zhou Q; Wu F; Zhang W; Guo Y; Jiang X; Yan X; Ke Y
    J Cell Mol Med; 2024 Jun; 28(11):e18463. PubMed ID: 38847472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
    Thaci B; Ahmed AU; Ulasov IV; Wainwright DA; Nigam P; Auffinger B; Tobias AL; Han Y; Zhang L; Moon KS; Lesniak MS
    Cancer Gene Ther; 2014 Jan; 21(1):38-44. PubMed ID: 24434573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma.
    He J; Zeng C; Long Y
    Comput Math Methods Med; 2021; 2021():2191709. PubMed ID: 34497663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of
    Liu Z; Yang L; Xie Z; Yu H; Gu T; Shi D; Cai N; Zhuo S
    Oncol Res; 2024; 32(5):965-981. PubMed ID: 38686055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TGF-β Score based on
    Zhang W; Yan Z; Zhao F; He Q; Xu H
    Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions.
    Liu J; Piranlioglu R; Ye F; Shu K; Lei T; Nakashima H
    Front Cell Infect Microbiol; 2023; 13():1141034. PubMed ID: 37234776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Significance of the Redox Gene in the Prognosis and Therapeutic Response of Glioma.
    Niu H; Cao H; Liu X; Chen Y; Cheng Z; Long J; Li F; Sun C; Zuo P
    Am J Clin Oncol; 2024 Jun; 47(6):259-270. PubMed ID: 38318849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.
    Siret C; Collignon A; Silvy F; Robert S; Cheyrol T; André P; Rigot V; Iovanna J; van de Pavert S; Lombardo D; Mas E; Martirosyan A
    Front Immunol; 2019; 10():3070. PubMed ID: 32038621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.